Pharmacogenetics of chronic cardiovascular drugs: applications and implications

Area of Science:

• Pharmacology
• Genetics
• Cardiology

Background:

• Cardiovascular diseases (CVD) pose a significant global health challenge.
• Current pharmacological management of CVD (hypertension, dyslipidemia, heart failure) often relies on empirical, trial-and-error methods.
• This conventional approach may not meet the diverse therapeutic needs of all patients.

Purpose of the Study:

• To review pharmacogenetic studies of common cardiovascular drugs.
• To highlight the potential of pharmacogenetics in tailoring drug therapy for individual patients.
• To identify future research directions and clinical practice considerations.

Main Methods:

• Literature review of pharmacogenetic studies.
• Analysis of research on drug response variability.
• Synthesis of findings related to specific cardiovascular drug classes.

Main Results:

• Pharmacogenetics offers a pathway to personalized cardiovascular medicine.
• Variability in patient response to diuretics, beta-blockers, ACE inhibitors, ARBs, statins, and warfarin is influenced by genetic factors.
• Evidence supports the use of pharmacogenetics to optimize drug selection and dosing.

Conclusions:

• Pharmacogenetics is a valuable tool for enhancing patient-specific cardiovascular drug therapy.
• Integrating pharmacogenetic insights into clinical practice can improve treatment efficacy and reduce adverse events.
• Further research is crucial to fully realize the potential of pharmacogenetics in CVD management.